🇺🇸 HUTCHMED (China) LtdHCM

Company Update Form 6-K 19-11-2026 06:02:50 EST

Subject: 6-K — Foreign issuer report

Overview: Announces preclinical data for HMPL-A830 and China NMPA approval of SYVIK® (sovleplenib) for treating primary ITP and warm antibody autoimmune hemolytic anemia.

Source: SEC EDGAR · Original filing

Open document in a new tab

Get filings like this in Telegram the moment they are published — for the companies you follow.

Start 30-day trial About Finterest